A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposu...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 1, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 1, 2026
Connect with organizations supporting the herpes zoster community
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 1, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning herpes zoster
Updated May 19, 2008
CDC recommends that individuals aged 60 and older receive the shingles vaccine to prevent herpes zoster, which can lead to chronic pain. This guidance aims to enhance awareness and vaccination rates among older adults.
The CDC's Advisory Committee on Immunization Practices recommends a new shingles vaccine for individuals aged 60 and older, aiming to reduce the incidence of herpes zoster and its associated chronic pain. This recommendation could influence vaccination policies and access for older adults.